Funding

Signadori Bio

France · Biotech · Healthtech

Develops in vivo engineered monocyte immunotherapy to treat solid tumours in preclinical stage

Visit signadoribio.comFunding history

Funding history

1 round · 1 with disclosed amounts
AnnouncedRoundAmountInvestors
Seed+€11.1MInvivo Partners — Role not disclosedSofinnova Partners — Role not disclosedTaiho Ventures — Role not disclosed

Investors

Invivo PartnersSeed+Sofinnova PartnersSeed+Taiho VenturesSeed+

Coverage

May 6, 2026Signadori Bio · Seed+

Similar companies

Guoke Brain-ComputerBeijing startup developing non-invasive wearable brain-computer interfaces that combine brain-signal detection, decoding and neural modulation.Undisclosed · Seed
Pathos AIClinical-stage drug developer using AI to select therapeutic assets and guide oncology trials.$237M · Series E
Star TherapeuticsBiotechnology company discovering and developing antibody therapies for diseases with significant unmet need.$200M · Private financing
Sourcessignadoribio.com ↗